argenx SE (ARGX)
588.09
-7.49
(-1.26%)
USD |
NASDAQ |
Nov 04, 16:00
596.19
+8.10
(+1.38%)
Pre-Market: 08:44
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 35.17B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 17.63% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 19.28 |
Price to Book Value | 8.250 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 38.20% |
Profile
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
URL | https://www.argenx.com |
Investor Relations URL | https://us.argenx.com/investors |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Oct. 31, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
URL | https://www.argenx.com |
Investor Relations URL | https://us.argenx.com/investors |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Oct. 31, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |